公开(公告)号：US20140093454A1

公开(公告)日：2014-04-03

申请号：US13964956

申请日：2013-08-12

Applicant: Genmab A/S

Inventor： Jessica Teeling ,  Sigrid Ruuls ,  Martin Glennie ,  Jan G.J. van de Winkel ,  Paul Parren ,  Jørgen Petersen ,  Ole Baadsgaard ,  Haichun Huang

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/68 ,  A61K39/395

CPC classification number: C07K16/2887 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4258 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/686

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD20的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US12247065B2

公开(公告)日：2025-03-11

申请号：US17253286

申请日：2019-06-24

Applicant: GENMAB A/S

Inventor： Richard Hibbert ,  Rob De Jong ,  Aran Frank Labrijn ,  Arnout Gerritsen ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/00 ,  C07K1/18 ,  C07K1/22

Abstract: The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

公开(公告)号：US20240084036A1

公开(公告)日：2024-03-14

申请号：US17972867

申请日：2022-10-25

Applicant: Genmab A/S

Inventor： Joost J. NEIJSSEN ,  Bart De Goeij ,  Edward Norbert Van Den Brink ,  Aran Frank Labrijn ,  Rene Hoet ,  Janine Schuurman ,  Paul Parren ,  Jan Van De Winkel

IPC: C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  G01N33/574

CPC classification number: C07K16/3076 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2863 ,  C07K16/40 ,  G01N33/5748 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/71 ,  G01N2333/912

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US11613575B2

公开(公告)日：2023-03-28

申请号：US16544376

申请日：2019-08-19

Applicant: GENMAB A/S

Inventor： Edward Norbert Van Den Brink ,  Joost J. Neijssen ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Isil Altintas ,  Paul Parren ,  Rik Rademaker

IPC: A61P35/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/10 ,  C07K16/42 ,  G01N33/68 ,  A61K39/00

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US11130819B2

公开(公告)日：2021-09-28

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11091553B2

公开(公告)日：2021-08-17

申请号：US15832337

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart De Goeij ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  Jan Van De Winkel ,  David Satijn ,  Paul Parren ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Edward N. Van Den Brink

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US10752695B2

公开(公告)日：2020-08-25

申请号：US15197496

申请日：2016-06-29

Applicant: GENMAB A/S

Inventor： Jan Van De Winkel ,  Tom Vink ,  Janine Schuurman ,  Paul Parren ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschoten

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K51/10 ,  A61K47/68 ,  C07K16/16 ,  C07K16/18 ,  C07K1/00 ,  A61K39/00

Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

公开(公告)号：US10703818B2

公开(公告)日：2020-07-07

申请号：US15420824

申请日：2017-01-31

Applicant: GENMAB A/S

Inventor： Janine Schuurman ,  Catharina Emanuele Gerarda Havenith ,  Paul Parren ,  Jan G. J. Van De Winkel ,  Denise Leah Williams ,  Jørgen Petersen ,  Ole Baadsgaard

IPC: C07K16/20 ,  C07K16/30 ,  C07K16/40 ,  C07K16/28 ,  G01N33/68 ,  A61K39/395 ,  A61K45/06 ,  A61N5/06 ,  C07K16/42 ,  C07K16/46 ,  G01N33/574 ,  G01N33/569 ,  A61K39/00

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US10590206B2

公开(公告)日：2020-03-17

申请号：US14760157

申请日：2014-01-09

Applicant: GENMAB A/S

Inventor： Aran Frank Labrijn ,  Joyce Meesters ,  Joost J. Neijssen ,  Edward Norbert Van Den Brink ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10 ,  C07K16/36 ,  C07K16/00 ,  C07K16/32 ,  C07K16/12 ,  A61K39/00

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

公开(公告)号：US10344050B2

公开(公告)日：2019-07-09

申请号：US14353962

申请日：2012-10-26

Applicant: GENMAB A/S

Inventor： Michael Gramer ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kampen ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Arnout Gerritsen

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/46 ,  C07K1/113

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.